General Information of DTT (ID: TTIVDM3)

DTT Name Voltage-gated potassium channel Kv7.3 (KCNQ3) DTT Info
Gene Name KCNQ3

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Retigabine DMGNYIH Behcet disease 4A62 Approved [1]
------------------------------------------------------------------------------------
3 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Linopirdine DM0ZOGX Cognitive impairment 6D71 Phase 3 [2]
ICA-105665 DMP925B Epilepsy 8A60-8A68 Phase 2 [3]
XEN1101 DMJVL57 Epilepsy 8A60-8A68 Phase 1 [4]
------------------------------------------------------------------------------------
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ICA-69673 DM1RZVI Pain MG30-MG3Z Preclinical [5]
------------------------------------------------------------------------------------
2 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
PD-32577 DMBA15J Discovery agent N.A. Investigative [6]
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [7]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12.
2 The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40.
3 New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52.
4 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
5 Voltage-gated Potassium Channels as Therapeutic Drug Targets
6 Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
7 Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol. 2000 Feb;129(3):413-5.